YAP1 and non-small cell lung carcinoma: Silencing of YAP1 significantly counteracted osimertinib resistance, whereas overexpression of YAP1 greatly inhibited osimertinib sensitivity, supporting the notion that YAP1 promotes drug resistance in NSCLC.